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Portal hypertension is the main cause of complications in patients with cirrhosis. However, evaluating the development and
progression of portal hypertension represents a challenge for clinicians. There has been considerable focus on the potential
role of noninvasive markers of portal hypertension that could be used to stratify patients with respect to the stage of portal
hypertension and to monitor disease progression or treatment response in a longitudinal manner without having to undertake
repeated invasive assessment. The pathogenesis of portal hypertension is increasingly understood and emerging knowledge of
the vascular processes that underpin portal hypertension has paved the way for exploring novel biomarkers of vascular injury,
angiogenesis, and endothelial dysfunction. In this paper we focus on the pathogenesis of portal hypertension and potential non-
invasive biomarkers with particular emphasis on serum analytes.
1. Clinical Importance of Portal Hypertension
Portal hypertension (PHT) is the most important conse-
quence of cirrhosis and its presence is a hard endpoint
for clinically relevant outcomes in terms of varices, ascites,
hepatorenal syndrome, and encephalopathy [1]. The cur-
rent gold standard for measuring PHT and its severity
is measurement of the hepatic venous pressure gradient
(HVPG). The prognostic value of PHT measurement at
diﬀerent stages in the natural history of chronic liver disease
is well established, with cut-oﬀ values for the development
of complications (HVPG > 10mmHg) and variceal rupture
(HVPG > 12mmHg) [2, 3]. A reduction in HVPG (e.g., after
drug therapy) below 12mm Hg or by >20% from baseline
is associated with a significant reduction in complications
and death. In addition, HVPG is also emerging as a reliable
endpoint to assess disease progression and therapeutic
response in chronic liver disease. The importance of PHT is
summarised in Figure 1 showing how changes in the HVPG
aﬀect clinical outcomes. Although HVPG measurement is
safe and relatively simple to perform, it is invasive, costly, and
only performed in specialist centres [4]. A recommendation
from the Baverno V Consensus Workshop on Methodology
of Diagnosis and Therapy in PHTwas to identify noninvasive
tools for detecting PHT [5], which could have clinical utility
for monitoring changes in PHT over time.
2. Pathophysiology of Portal Hypertension
In cirrhosis, PHT is initiated by an increase in intrahepatic
vascular resistance (IHVR) and then exacerbated by changes
in the systemic and splanchnic circulation that increase the
portal inflow. Increased IHVR is caused not only by mechan-
ical factors (e.g., fibrotic scars and regenerative nodules
that distort the hepatic vascular architecture), but also by a
reversible dynamic component mediated by an increase in
vascular tone due to the active contraction of myofibroblasts
around the hepatic sinusoids and in fibrous septa (Figure 2).
This dynamic component (which accounts for ∼30% of
increased IHVR) reflects a functional disturbance of the
liver circulation, secondary to increased production of
vasoconstrictors (e.g., endothelin-1) and reduced release of
endogenous vasodilators (mainly nitric oxide, NO) [6–9].
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Ripoll et al. (2007) [3]
Groszmann et al. 2005 [2]
Villanueva et al. 1996 [6]
Moitinho et al. 1999 [7]
Figure 1: Clinical importance of portal hypertension.
Decreased expression of endothelial NO synthase (eNOS)
protein, decreased phosphorylation of eNOS by the serine-
threonine kinase AKT, the presence of inhibitory substances
(e.g., asymmetric dimethylarginine, ADMA), and hypore-
sponsiveness to NO underlie this endothelial dysfunction
[10–12]. In contrast, extrahepatic endothelial cells have
the opposite phenotype producing excessive NO which
contributes to increased portal blood flow and an increase
in PHT.
Angiogenesis has also been shown to influence PHT, with
studies demonstrating that the maintenance of increased
portal pressure, hyperkinetic circulation, splanchnic neovas-
cularization, and portosystemic collateralization is regulated
by vascular endothelial growth factor (VEGF) and platelet-
derived growth factor (PDGF) [13].
There has been considerable interest in the identification
of reliable noninvasive biomarkers for PHT including imag-
ing techniques, routine laboratory tests, serum markers of
inflammation and fibrosis, and quantitative assays of liver
function which have all shown varying levels of diagnostic
accuracy for PHT. The role of imaging markers has been
comprehensively addressed in recent reviews [14–16]. The
aim of this paper is to review the potential role of noninvasive
techniques in evaluating PHT. We have focussed on serum
biomarkers with particular emphasis on those that have been
identified as being involved in the pathogenesis of PHT.
These include novel serum markers associated with vascular
injury, angiogenesis, and altered endothelial phenotypes.
3. Assessment of Simple Clinical Parameters
3.1. Clinical Manifestations of PHT. There are several clinical
features that indicate the presence of PHT including ascites,
splenomegaly, and caput medusa. Hypotension and tachy-
cardia may reflect a hyperkinetic circulation. However, these
signs often develop late in the natural history of PHT, can
be caused by other diseases, (e.g., portal vein thrombosis or
malignancy), and their presence varies between patients. A
systematic review of the diagnostic accuracy of physical find-
ings established that they had low sensitivity in compensated
disease [17].
3.2. Platelet : Spleen Ratio (Giannini Index). Thrombocyto-
paenia (platelet count <150,000/uL) is a common com-
plication in patients with chronic liver disease. Moderate
thrombocytopaenia (platelet count 50,000–75,000) occurs in
∼13% of patients with cirrhosis. Multiple factors can con-
tribute to the development of thrombocytopaenia, including
splenic platelet sequestration, bone marrow suppression by
chronic hepatitis C infection, and antiviral treatment with
interferon-based therapy. Reductions in the level or activity
of the haematopoietic growth factor thrombopoietin (TPO)
may also play a role. Thrombocytopaenia has been shown
to be an independent predictor of significant PHT and the
presence of varices, with HVPG and platelet count showing
significant negative correlation [18]. However, no specific
platelet value has been found to accurately predict the pres-
ence of varices and although there is a statistical correlation,
a change in the platelet count is not a reliable surrogate
of reciprocal changes in portal pressure/HVPG [19]. When
combined as the platelet : spleen ratio by Giannini, a 100%
negative predictive value for presence of varices with a ratio
of over 909 was shown [20]. This ratio has been validated and
is simple and cheap [21]. However, criticisms of this simple
test are that thrombocytopaenia is often a late sign of PHT,
it can occur due to other conditions such as bone marrow
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Figure 2: Schematic representation of the pathophysiology of portal hypertension with corresponding potential noninvasive markers. TE:
transient elastography; MRI(E): magnetic resonance imaging (elastography); US: ultrasound; CECs: circulating endothelial cells; ADMA:
asymmetric dimethylarginine; vWF: von Willebrand factor; ET-1: endothelin-1; MELD: Model for End-Stage Liver Disease.
suppression, and there is a degree of interobserver variability
when measuring the spleen size.
It is worth noting that splenomegaly in cirrhosis is not
simply caused by portal congestion, but is mainly due to
tissue hyperplasia and fibrosis. Although a slight reduction
in spleen size has been reported after liver transplantation
for cirrhosis [22], evidence of regression of splenomegaly
in parallel with a reduction in portal pressure is lacking.
Indeed, complete resolution of splenomegaly has never been
described, presumably because the architectural changes are
at least in part irreversible. This calls into question the utility
of splenomegaly as a dynamic marker of PHT.
3.3. Serum Markers of Hepatic Failure. The degree of hepatic
failure as indicated by low albumin, prolonged prothrombin
time, raised bilirubin, or stratification by Child-Pugh score
has been shown in various studies to correlate with severe
PHT and the prevalence/grade of varices. However none have
been shown to correlate with the degree of PHT and are
therefore not accurate enough to determine the severity of
PHT in clinical practice [18, 19, 23].
4. Assessing the Structural Component of PHT
4.1. Serum Markers of Hepatic Fibrosis. The extent of hepatic
fibrosis influences IHVR and therefore portal pressure, which
would suggest that markers of fibrosis may also act as
markers of PHT [24]. However, there have been relatively
few studies exploring the use of serum fibrosis markers in
PHT. Examples of potential analytes include constituents of
the basal lamina (e.g., laminin) ormajor constituents of loose
connective tissue (e.g., hyaluronic acid). These markers are
found in the blood and have been correlated with hepatic
fibrosis [25]. Several studies have shown that serum laminin
levels correlate with HVPG in patients with fibrosis and com-
pensated cirrhosis [26, 27]. For the prediction of severe PHT
(HVPG > 12mmHg), serum laminin had a positive predic-
tive value (PPV) of 85% and negative predictive value (NPV)
of 43% [28]. Correlation has also been shown between the
serum hyaluronic acid concentration and HVPG [29]. To
date, studies have only involved small numbers of patients
and larger-scale studies are needed to determine the clinical
utility of serum fibrosis markers for the evaluation of PHT.
FibroTest (FT) is a panel of biochemical markers that
has been extensively validated for the diagnosis of advanced
fibrosis and cirrhosis [14]. Thabut and coworkers conducted
a prospective study in 130 patients (with or without cirrho-
sis) undergoing transjugular liver biopsy. The HVPG was
also measured along with serum collection for FT. There
was significant correlation between FT and HVPG, but this
correlation was weaker in patients with established cirrhosis.
The FT result was significantly higher in those with PHT,
the area under the receiver operator curve (AUROC) for the
diagnosis of severe PHT (HVPG > 12) was 0.79, indicating
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that this test was not superior to platelet count or Child-Pugh
score (0.79 and 0.78, resp.) in diagnosing PHT [30]. Another
study performed in 268 patients with chronic hepatitis C
compared FT to other potential markers of PHT. For FT, the
AUROC for the diagnosis of all varices was 0.72 and 0.76
for large varices, with a sensitivity of only 70% [16]. Despite
showing promise, FT has not yet been shown to be a reliable
test for clinically significant PHT.
4.2. Measurement of Liver Stiﬀness. The role of transient
elastography (TE) has been explored in several reviews
[14, 15]. The degree of liver stiﬀness has been shown to
strongly predict the presence of advanced fibrosis or cirrhosis
[31] and also correlates with HVPG. A very recent study
by Robic and colleagues showed that the liver stiﬀness
measurement (LSM) can be as useful as HVPG in predicting
clinical decompensation and PHT-related complications
[32]. In this study an LSM of 21.1 kPa or greater gave
an AUROC of 0.845 for predicting portal hypertensive
complications, with HVPG giving an AUROC of 0.837.
No patients with an LSM <21.1 kPa developed any portal
hypertensive-related complications. TE is therefore emerging
as a leading diagnostic marker for PHT, although a major
disadvantage of this technique is the inability to interpret
scans in nearly 1 in 5 cases mostly due to obesity and
limited operator experience [33]. Additionally, outside of
specialist centres, many hospitals may not have access to
this resource. Magnetic resonance elastography (MRE) is
a promising modality for the noninvasive assessment of
liver fibrosis. MRE of the spleen is also feasible and has
shown promise as a quantitative method for predicting the
presence of oesophageal varices in patients with advanced
liver fibrosis [34]. However, MRE is currently too expensive
and time consuming for widespread implementation in
clinical practice.
4.3. Serum Markers of Angiogenesis. Both VEGF and PDGF
are critical to angiogenesis, a process that contributes
significantly to PHT by expanding the splanchnic vascular
bed and thereby increasing portal blood flow. In addition,
VEGF-dependent angiogenesis is important in portosys-
temic collateral vessel formation including varices. VEGF
plays the predominant role in stimulating proliferation of
endothelial cells and endothelial tube formation, whereas
PDGF regulates vessel stability via the attachment of mural
and pericyte cell populations to the endothelium. Increased
VEGF expression has been shown by immunohistochemistry
and western blot in the mesenteric vessels of animals with
PHT, with levels correlating with increasing PHT [35]. Com-
bined blockade of VEGF and PDGF after the development of
PHT significantly decreased portal pressure and mesenteric
blood flow with reduced expression of VEGF and PDGF
[13]. Interestingly, this eﬀect was not observed in models
where PHT was just developing. In a model of carbon-
tetrachloride- (CCl4-) induced cirrhosis, animals with PHT
had significantly increased levels of intestinal and plasma
VEGF but there was no correlation between plasma VEGF
levels and portal pressure [36]. This contrasts with a small
human study investigating the role of Octreotide in PHT
which showed a significant correlation between HVPG and
the serum VEGF level [37]. It appears that VEGF and PDGF
have a synergistic interaction in the pathogenesis of PHT
through regulation of splanchnic neovascularisation and
portosystemic collateral formation. However, data to support
a diagnostic role for these markers in PHT is currently
lacking.
In patients with cirrhosis, serum levels of soluble vascular
adhesion molecule (sVCAM-1) have been associated with
increasing liver fibrosis and are related to angiogenesis.
Although serum sVCAM-1 levels did not correlate with
HVPG, it could represent a marker of the hyperkinetic
circulation and levels were closely related to clinical stage
(Child-Pugh, MELD scores) [38].
5. Dynamic Functional Component of
Portal Hypertension
5.1. Markers of Increased Vasoconstriction. As PHT is associ-
ated with hyperproduction of endogenous vasoconstrictors,
measurement of these factors in the serum could be used
to evaluate PHT noninvasively. Serum endothelin-1 (ET-1)
levels are elevated in portopulmonary hypertension and
associated with a poor outcome [39] and have also been
shown to correlate with HVPG values in patients with
cirrhosis [40]. Thus, serum endothelin levels could be used
to evaluate the degree of PHT, although further studies are
needed to determine the clinically relevant levels.
Urotensin II (U-II), a somatostatin-like cyclic peptide,
was recently identified as the most potent human vaso-
constrictor peptide. One study suggested that U-II was
an important marker of the severity of PHT in children
with chronic liver disease and correlated with Child-Pugh
score, paediatric end-stage liver disease score, and long-
term clinical outcome [41]. In another study, in adults
with cirrhosis and hyperkinetic circulation but with normal
serum creatinine, U-II levels were notably higher than in
healthy subjects; however there was no correlation with
cardiac index or other haemodynamic parameters observed
[42].
5.2. Markers of Endothelial Dysfunction. Endothelial dys-
function is a major determinant of the increased intrahepatic
vascular tone observed in cirrhosis and a number of markers
reflecting this dysfunction have been identified.
NO synthesis can be inhibited by the endogenous circu-
lating amino acid asymmetric dimethylarginine (ADMA).
ADMA is synthesized via enzymatic methylation of L-
arginine residues in proteins and is released during pro-
teolysis and metabolized to citrulline and dimethylamine
in the liver, with impaired liver function associated with
increased plasma levels of ADMA. There have been sev-
eral studies linking ADMA to endothelial dysfunction in
cardiovascular disease and multiorgan failure [43, 44].
Laleman and colleagues examined diﬀerent animal models
of cirrhosis and PHT and showed that bile-duct-ligated
(BDL) animals exhibited normal eNOS levels in contrast
International Journal of Hepatology 5
to thioacetamide and carbon-tetrachloride-induced models
of cirrhosis, suggesting that posttranslational regulatory
mechanisms are involved in the defective production of NO
in some causes of cirrhosis [12]. In BDL-treated animals
ADMA levels were significantly elevated suggesting a possible
role for ADMA in inhibiting eNOS. Lluch and coworkers
showed that peripheral blood levels of ADMA correlated
with the degree of liver failure and decompensation in
patients with alcohol-related cirrhosis [45]. In a further study
involving patients with compensated chronic hepatitis C
cirrhosis, a positive statistically significant correlation was
found between HVPG and ADMA [46]. This was the first
study to observe a correlation between the degree of PHT
and ADMA levels. Further mechanistic studies are needed to
define ADMA metabolism and function in PHT.
Von Willebrand factor (vWF), P-selectin, and 8-iso-
PGF2a have also been identified as surrogate markers of
endothelial dysfunction and levels of these factors are
increased in patients with cirrhosis compared with controls.
In patients with PHT, vWF levels significantly correlated
with HVPG, Child-Pugh, and MELD scores. In addition,
peripheral vWF levels with a cut-oﬀ value of 216 U/dL
(Youden index) were also predictive of clinical outcomes
(PHT-related events and liver transplantation) [47].
5.3. Markers of Vascular Injury: Circulating Endothelial Cells
(CECs). CECs are a specific population of endothelial cells
in peripheral blood. They exceed 10 µm in size and are
characterized by the expression of at least two diﬀerent
endothelial markers and absence of expression of leukocyte
markers [48]. They are present in very low levels in healthy
individuals. Elevated levels of CECs have been observed
in a variety of diseases associated with vascular damage
and are considered to reflect the severity of vascular injury
[11]. Abdelmoneim and colleagues [49] performed a small
study on patients with cirrhosis, with or without PHT, the
latter being defined by the presence of varices, splenomegaly,
ascites, encephalopathy, and/or HCC versus age- and sex-
matched controls. The number of CECs was significantly
elevated in patients with cirrhosis compared to controls.
However, HVPG was not measured in these subjects such
that conclusions regarding the clinical potential of CECs
as a biomarker for PHT are limited. When combined with
the platelet count (PC) as CEC/PC with a cut-oﬀ value
of 0.21, the sensitivity for diagnosing cirrhosis was 100%
with a specificity of 73% and AUROC of 0.8. Additionally
correlation was seen with a rising CEC/PC and presence of
decompensation. A further larger study is needed in patients
where CECs levels and CEC/PC are correlated with the
HVPG.
6. Markers of Modifications in Splanchnic
Circulation and Hyperkinetic Syndrome
The extrahepatic endothelial phenotype is that of excess NO
production causing peripheral vasodilatation and increased
blood flow through the mesenteric vessels and portal vein.
This exacerbates the portal pressure. Imaging of the portal
and systemic circulation has been performed using duplex
Doppler ultrasound, CT, and MRI. Detailed discussion of
these modalities is beyond the scope of this paper but
noninvasive imaging has shown promise in detecting por-
tosystemic collaterals and changes in portal vein expiration
diameter, hepatic vein waveforms, and splenic pulsatility
which all have varying discriminatory ability in detecting
changes in PHT [14].
7. Video Capsule Endoscopy (VCE)
The presence of varices is objective evidence of the presence
of severe PHT. Rather than pure search for surrogate markers
of PHT, there has been much interest in the use of capsule
endoscopy in diagnosing varices. Promising results in pilot
studies led to two larger studies. De Franchis et al. [50]
showed, in a study of 288 cirrhotic patients undergoing
endoscopy for either screening or surveillance, that VCE had
84% sensitivity and 92% PPV for detecting all oesophageal
varices. For determining the size of the varices and need
for surveillance versus treatment, it was shown that VCE
had an 87% PPV and 92% NPV suggesting that as a
noninvasive tool it is promising [50]. Lapalus et al. [51]
showed similar encouraging results in a study of 120 patients
with PHT undergoing VCE followed by endoscopy. They
found VCE had 77% sensitivity and 90% PPV for diagnosing
oesophageal varices [51]. Concordance between the two
blinded endoscopists was good, particularly with regard to
who required prophylaxis. However, recent evidence from
a clinical study by Chavalitdhamrong et al. [52] has shown
overall accuracy for detection of oesophageal varices at only
63.2% with 51.5% sensitivity for other significant upper GI
lesions such as portal hypertensive gastropathy or gastric
varices, suggesting that there are fairly major discrepancies
in the sensitivity and specificity between operators [52]. It is
clear that standard endoscopy is superior to VCE. Although
it does show promise as a noninvasive tool, its role may be in
patients who require screening whilst on treatment, but do
not tolerate standard endoscopy well.
8. Conclusion
PHT is a robust outcome measure which has proven prog-
nostic significance in chronic liver disease and the potential
for use in monitoring disease progression and treatment
eﬃcacy. In this paper we have outlined the pathogenesis of
PHT and discussed a range of candidate serum biomarkers
that have been identified. At present, transient elastography
appears to represent the most promising noninvasive tech-
nique that could potentially replace HVPG measurement
for PHT or endoscopy for variceal detection. The potential
role of serum markers for the evaluation of PHT remains
unproven, but will increasingly be assessed in prospective
clinical studies. Further advances in our understanding of
the underlying mechanisms responsible for the development
and progression of PHT will continue to reveal additional
biomarker targets.
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9. Methods
Referred papers were identified byMEDLINE search through
the PubMed database by combining the keyword “portal
hypertension” with the keywords “biomarkers, serum, fibro-
sis, endothelial cell and angiogenesis.” Additional papers
were identified by searching of references through retrieved
papers.
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